covid
Buscar en
Revista Colombiana de Anestesiología
Toda la web
Inicio Revista Colombiana de Anestesiología Consideraciones anestésicas en la enfermedad de Parkinson
Información de la revista
Vol. 36. Núm. 3.
Páginas 207-215 (agosto - octubre 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 36. Núm. 3.
Páginas 207-215 (agosto - octubre 2008)
ARTÍCULO DE REVISIÓN
Open Access
Consideraciones anestésicas en la enfermedad de Parkinson
Visitas
6223
Miguel Arango*, Ruby Molina**
* Neuroanestesiólogo, Departamento de Anestesia y Medicina Perioperatoria LHSC, London, Canadá
** Neuroanestesia, Hospital Santo Tomás, Ciudad de Panamá, Panamá
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
RESUMEN

La enfermedad de Parkinson es un trastorno neurológico degenerativo que causa alteraciones motoras, autonómicas, sistémicas y psiquiátricas, cuyo inicio suele ser después de los 60 años de edad.

Los cambios fisiopatológicos que se desarrollan en la enfermedad de Parkinson, el incremento de la expectativa de vida de nuestra población y las posibles interacciones de los anestésicos con la terapia farmacológica dirigida al control de los síntomas del Parkinson, imponen situaciones especiales en el ámbito perioperatorio y justifican el conocimiento del tema para el anestesiólogo.

El propósito de este manuscrito es revisar las características que hacen especial el manejo perioperatorio de este grupo de pacientes y resumir las opciones y recomendaciones descritas al respecto, enfocándonos en los procedimientos no neurológicos a los que suelen ser sometidos.

Key words:
Parkinson's disease
anesthesia
perioperative care
Palabras clave:
enfermedad de Parkinson
anestesia
cuidado perioperatorio
ABSTRACT

Parkinson's disease is a neurodegenerative pathology that causes motor, autonomic, systemic and psychiatric alterations, which start usually after 60 years of age.

The physiopathological changes that develop during this disease, the increasing life expectancy of our population, and the possible interactions between anesthetics and pharmacological therapy used to manage Parkinson's symptoms impose special situations in the perioperative scenario and justify the knowledge about this topic for the anesthesiologist.

The aim of this manuscript is to review the characteristics that make the perioperative management of this group of patients special, and summarizes the options and recommendations described in the matter, with focus on the non-neurological procedures that they would normally be subject to.

El Texto completo está disponible en PDF
REFERENCIAS
[1.]
S. Gilman.
Parkinsonian syndromes.
Clin Geriatr Med, 22 (2006), pp. 827-842
[2.]
J. Benito-León, J. Porta-Etessam, F. Bermejo.
Epidemiología de la enfermedad de Parkinson.
Neurología, 13 (1998), pp. 2-7
[3.]
J. Parkinson.
An essay on the shaking palsy.
Whittingham & Rowland, (1817),
[4.]
A.H.V. Schapira.
Parkinson's disease.
BMJ, 318 (1999), pp. 311-314
[5.]
K. Shannon.
Movement disorders in neurology in clinical practice.
4th edition, pp. 2125-2165
[6.]
V. Kumar.
Robbins and Cotran Pathologic basis of disease.
7th edition, pp. 1385-1397
[7.]
J. Chacón, L. Dinca-Avarvarei, J. Acosta, M. Pastor-Cruz, J. Burguera-Hernández.
Parkinson de inicio precoz.
Rev Neurol, 45 (2007), pp. 323-327
[8.]
S. Rao, L. Hofmann, A. Shakil.
Parkinson's disease.
Am Fam Physician, 74 (2006), pp. 2046-2054
[9.]
M.S. Forman, J.Q. Trojanowski, V.M. Lee.
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.
Nat Med, 10 (2004), pp. 1055-1063
[10.]
R.L. Albin.
Parkinson's disease: background, diagnosis, and initial management.
Clin Geriatr Med, 22 (2006), pp. 735-751
[11.]
L.J. Mason, T.T. Cojocaru, D.J. Cole.
Surgical intervention and anesthetic management of the patient with Parkinson's disease.
Int Anesthesiol Clin, 34 (1996), pp. 133-150
[12.]
H. Morgado, M. Alonso, M. López.
Factores genéticos involucrados en la susceptibilidad para desarrollar enfermedad de Parkinson.
Salud Mental, 30 (2007), pp. 16-24
[13.]
M.F. Allam, M.J. Campbell, A. Hofman.
Smoking and Parkinson's disease: systemic review of prospective studies.
Mov Disord, 19 (2004), pp. 614-621
[14.]
T. Wichmann, M.R. DeLong.
Pathophysiology of parkinsonian motor abnormalities.
Adv Neurol, 60 (1993), pp. 53-61
[15.]
H. Braak, E. Ghebremedhin, U. Rub, H. Bratzke, K. Del Tredici.
Stages in the development of Parkinson's disease-related pathology.
Cell Tissue Res, 318 (2004), pp. 121-134
[16.]
J. Jankovic, A. Lang.
Movement disorders: diagnosis and assessment.
Neurology in Clinical Practice, 4th edition, pp. 294-318
[17.]
F. Stella, L.T. Bucken-Gobbi, S. Gobbi, C. Sant'Ana-Simoes.
Síntomas depresivos y trastorno motor en pacientes con enfermedad de Parkinson.
Rev Neurol, 45 (2007), pp. 594-598
[18.]
G. Nicholson, A. Pereira, G. Hall.
Parkinson's disease and anaesthesia.
Br J Anaesth, 89 (2002), pp. 904-916
[19.]
J. Jankovic.
Parkinson's disease therapy of early and late disease.
Chin Med J, 114 (2001), pp. 227-234
[20.]
D. Aarsland, U. Mosimann, I. McKeith.
Role of cholinesterase inhibitors in Parkinson's disease and dementia with lewy bodies.
J Geriatr Psychiatry Neurol, 17 (2004), pp. 164-171
[21.]
A. Qaseem, V. Snow, T. Cross, M. Forclea, R. Hopkins, P. Shekelle.
Current pharmacologic treatment of dementia: a clinical practice guideline from the ACP and the American academy of family physicians.
Ann Intern Med, 148 (2008), pp. 370-378
[22.]
N. Belluardo, G. Mudó, M. Blum, K. Fuxe.
Central nicotinic receptors, neurotrophic factors and neuroprotection.
Behavioural Brain Research, 113 (2000), pp. 21-34
[23.]
V. Fodale, C. Praticó, L.B. Santamaria.
Letter to the editor. Parkinsonism and related disorders.
PARKINSONISM and related disorders es el nombre de la revista, se trata de un comentario un comentario que se hizo a través de una carta al editor, 10 (2004), pp. 189-190
[24.]
J.M. Miyasaki, K. Shannon, V. Voon.
Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinson's disease (an evidence based review).
[25.]
A.J. Espay, G.T. Mandybur, F.J. Revilla.
Surgical treatment of movement disorders.
Clin Geriatr Med, 22 (2006), pp. 813-825
[26.]
J. Sear.
Implication of aging on anesthetic drugs.
Curr Opin Anaesthesiol, 16 (2003), pp. 373-378
[27.]
T. Yoshida, I. Kono, K. Yoshikawa, H. Hashimoto, H. Harada, M. Nakagawa.
Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a poly somnographic study.
Intern Med, 42 (2003), pp. 1135-1138
[28.]
D.A. Burton, G. Nicholson, G.M. Hall.
Anaesthesia in elderly patients with neurodegenerative disorders: special considerations.
Drugs Aging, 21 (2004), pp. 229-242
[29.]
Y. Kim, M. Cho, S. Kim.
Profound hypotension immediately following insertion of methyl methacrylate during bipolar endoprothesis in a patient with long-term levodopa-treated paralysis agitans (Parkinson's disease).
Journal of Korean Medical Science, 10 (1995), pp. 31-35
[30.]
G. Jurkovich.
Environmental cold-induced injury.
Surg Clin North Am, 87 (2007), pp. 247-267
[31.]
S. Insler, D. Sessler.
Perioperative thermoregulation and temperature monitoring.
Anesthesiol Clin, 24 (2006), pp. 823-837
[32.]
A.P. Reed, D.G. Han.
Intraoperative exacerbation of Parkinson's disease.
Anesth Analg, 75 (1992), pp. 850-853
[33.]
A. Carnini, M. Eckenhoff, R. Eckenhoff.
Interactions of volatile anesthetics with neurodegenerative-disease-associated proteins.
Anesthesiol Clin North Am, 24 (2006), pp. 381-405
[34.]
R. Eckenhoff, J. Johansson, H. Wei, A. Carnini, B. Kang, W. Wei.
Inhaled anesthetic enhancement of amyloid-B oligomerization and cytotoxicity.
Anesthesiology, 101 (2004), pp. 703-709
[35.]
V. Fodale, L.B. Santamaria.
Drugs of anaesthesia, central nicotinic receptors and post-operative cognitive dysfunction.
Acta Anaesthesiol Scand, 47 (2003), pp. 1180
[36.]
V. Fodale, L.B. Santamaria.
The inhibition of central nicotinic nACh receptors is the possible cause of prolonged cognitive impairment after anaesthesia.
Anesth Analg, 97 (2003), pp. 1207
[37.]
E. Tassonyi, E. Charpantier, D. Muller, L. Dumont, D. Bertrand.
The role of nicotinic acetylcholine receptors in the mechanisms of anaesthesia.
Brain Res Bull, 57 (2002), pp. 133-150
[38.]
E.A. El Maghrabi, R.G. Eckenhoff.
Inhibition of dopamine transport in rat brain synaptosomes by volatile anesthetics.
Anesthesiology, 78 (1993), pp. 750-756
[39.]
M. Ferro, M. Angelucci, J. Anselmo-Franci, N. Canteras, C. Da Cunha.
Neuroprotective effects of ketamine/xylazine on two rat models of Parkinson's disease.
Braz J Med Biol Res, 40 (2007), pp. 89-96
[40.]
J. Krauss, E.W. Akeyson, P. Giam, J. Jankovic.
Propofol-induced dyskinesias in Parkinson's disease.
Anesth Analg, 83 (1996), pp. 420-422
[41.]
V. Fodale, L.B. Santamaria.
Laudanosine, an atracurium and cisatracurium metabolite.
Eur J Anaesthesiol, 19 (2002), pp. 466-473
[42.]
V. Fodale, L.B. Santamaría.
The possible neuroprotective effect of laudanosine, an atracurium and cisatracurium metabolite.
Acta Anaesthesiol Scand, 47 (2003), pp. 780-781
[43.]
C.M. Garland, R.C. Foreman, J.E. Chad, L. Holden-Dye, R.J. Walker.
The actions of muscle relaxants at nicotinic aceylcholine receptor isoforms.
Eur J Pharmacol, 357 (1998), pp. 83-92
[44.]
P. Samadi, P. Bédard, C. Rouillard.
Opioids and motor complications in Parkinson's disease.
TRENDS in Pharmacological Sciences, 27 (2006), pp. 512-517
[45.]
D. Berg, G. Becker, K. Reiner.
Reduction of dyskinesia and induction of akinesia induced by morphine in two Parkinsonian patients with severe sciatica.
J Neural Transm, 106 (1999), pp. 725-728
[46.]
G.I. Zornberg, J.A. Bodkin, B.M. Colon.
Severe adverse interaction between pethidine and selegiline.
Lancet, 337 (1991), pp. 246
[47.]
M. Hanson, N. Gálvez-Jiménez.
Management of dementia and acute confusional states in the perioperative period.
Neurol Clin North Am, 22 (2004), pp. 413-422
[48.]
S. Muravchick, D. Smith.
Parkinsonian symptoms during emergence from general anesthesia.
Anesthesiology, 82 (1995), pp. 305-307
[49.]
W. Vincken, C. Darauay, M. Cosio.
Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease.
Chest, 96 (1989), pp. 210-212
[50.]
C. Chung, C. Li, C. Wong, F. Chen.
Pulmonary edema secondary to the airway obstruction in a patient with Parkinson's disease.
Acta Anaesthesiol Taiwan, 42 (2004), pp. 171-173
[51.]
L. Easdown, M. Tessler, J. Minuk.
Upper airway involvement in Parkinson's disease resulting in postoperative respiratory failure.
Can J Anaesth, 42 (1995), pp. 344-347
[52.]
B. Herer, I. Arnulf, B. Housset.
Effects of levodopa on pulmonary function in Parkinson's disease.
Chest, 119 (2001), pp. 387-393
[53.]
R. Furuya, A. Hirai, T. Andoh, I. Kudoh, F. Okumura.
Successful perioperative management of a patient with Parkinson's disease by enteral levodopa administration under propofol anesthesia.
Anesthesiology, 89 (1998), pp. 261-263
[54.]
M. Stacy, D. Silver.
Apomorphine for the acute treatment of “off” episodes in Parkinson's disease.
Parkinsonism and Related Disorders, 14 (2008), pp. 85-92
[55.]
V. Minville, C. Chassery, A. Benhaoua, V. Lubrano, P. Albaladejo, O. Fourcade.
Nerve stimulator-guided brachial plexus block in a patient with severe Parkinson's disease and bilateral deep brain stimulators.
[56.]
D.J. Stone, C.A. Difazio.
Sedation for patients with Parkinson's disease undergoing ophthalmology surgery.
Anesthesiology, 68 (1988), pp. 821
[57.]
C.D. Hanning.
Postoperative cognitive dysfunction.
Br J Anaesth, 95 (2005), pp. 82-87
[58.]
W.E. Golden, R.C. Lavender, W.S. Metzen.
Acute postoperative confusion and hallucinations in Parkinson's disease.
Ann Intern Med, 111 (1989), pp. 218
Copyright © 2008. Revista Colombiana de Anestesiología
Opciones de artículo